June 2017
Volume 58, Issue 8
Open Access
ARVO Annual Meeting Abstract  |   June 2017
Identification of a novel small molecule chaperon of rhodopsin and its therapeutic potential in retinal degeneration
Author Affiliations & Notes
  • Yuanyuan Chen
    Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States
  • Yu Chen
    Yueyang Hospital and Clinical Research Institute of Integrative Medicine, Shanghai University of Traditional Chinese Medicine, Shanghai, China
  • Beata Jastrzebska
    Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States
  • Hong Tang
    University of Cincinnati, Cincinnati, Ohio, United States
  • Xiaoyu Li
    Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States
  • William Siebel
    Cincinnati Children's Hospital, Cincinnati, Ohio, United States
  • Jianye Zhang
    Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States
  • Hui Jin
    Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States
  • Sahil Gulati
    Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States
  • Krzysztof Palczewski
    Pharmacology, Case Western Reserve University, Cleveland, Ohio, United States
  • Footnotes
    Commercial Relationships   Yuanyuan Chen, None; Yu Chen, None; Beata Jastrzebska, None; Hong Tang, None; Xiaoyu Li, None; William Siebel, None; Jianye Zhang, None; Hui Jin, None; Sahil Gulati, None; Krzysztof Palczewski, None
  • Footnotes
    Support  NIH K99 award EY024992
Investigative Ophthalmology & Visual Science June 2017, Vol.58, 253. doi:
  • Views
  • Share
  • Tools
    • Alerts
      ×
      This feature is available to Subscribers Only
      Sign In or Create an Account ×
    • Get Citation

      Yuanyuan Chen, Yu Chen, Beata Jastrzebska, Hong Tang, Xiaoyu Li, William Siebel, Jianye Zhang, Hui Jin, Sahil Gulati, Krzysztof Palczewski; Identification of a novel small molecule chaperon of rhodopsin and its therapeutic potential in retinal degeneration. Invest. Ophthalmol. Vis. Sci. 2017;58(8):253.

      Download citation file:


      © ARVO (1962-2015); The Authors (2016-present)

      ×
  • Supplements
Abstract

Purpose : P23H rhodopsin mutation disrupts rhodopsin proteostasis which leads to autosomal dominant retinitis pigmentosa (adRP) that is currently untreatable. We hypothesis that a small-molecule chaperon of rhodopsin will stabilize the P23H rhodopsin mutant and delay vision loss by restoring rhodopsin homeostasis in the retinal.

Methods : We performed a small-molecule high-throughput screening using a cell-based beta-galactosidase assay to quantify the rescued P23H opsin on the plasma membrane. A total of 78,520 molecules from a collection of three small molecule libraries were tested for their activities on rescuing the transport of P23H opsin and YC-001 was identified as an active lead compound. To characterize the mechanism of action of YC-001, we tested: 1) if YC-001 binds to rod opsin using a Trp fluorescence assay; 2) if YC-001 improves the glycosylation profile of P23H opsin by immunoblots; 3) if YC-001 protects retina from bright light-induced degeneration in Abca4-/- Rdh8-/- mice by administering 50 or 200 mg/kg by weight of YC-001 before exposing mice to bright light (10,000 lux, 30 min) followed by spectral domain optical coherence tomography (SD-OCT) and retinal histology imaging seven days later.

Results : YC-001 showed an EC50 at 7.8 μM with its efficacy at 310% compared to the effect of 5 μM 9-cis-retina in the beta-galactosidase fragment complementation assay. YC-001's effect on rescuing P23H opsin transport was confirmed by the immunostaining and high-content imaging assay showing an EC50 at 3.2 μM. YC-001 reversibly binds with the rod opsin in the bovine disc membrane with a Kd at 1 μM. Treatment with YC-001 improved the glycosylation profile of P23H opsin mutant in a dose-dependent manner, demonstrated as shifted bands in immunoblots. Mice preconditioned with YC-001 at 200 mg/kg by weight were resistant to bright light-induced retinal damage, revealed by SD-OCT and H&E retinal staining images with an outer nuclear layer comparable to that from mice without bright-light damage, whereas vehicle control group showed significant reduction of ONL thickness.

Conclusions : YC-001 is a novel small molecule chaperone of rhodopsin that prevents bright light-induced retinal degeneration in Abca4-/- Rdh8-/- mice, revealing its therapeutic potential of preventing retinal degenerations. Long-term treatment to P23H/+ mice will show if YC-001 will delay retinal degeneration for adRP.

This is an abstract that was submitted for the 2017 ARVO Annual Meeting, held in Baltimore, MD, May 7-11, 2017.

×
×

This PDF is available to Subscribers Only

Sign in or purchase a subscription to access this content. ×

You must be signed into an individual account to use this feature.

×